Creative Biolabs Launches End-to-End ASO Development Services to Streamline RNA Therapeutics

Creative Biolabs has announced the launch of its integrated, one-stop antisense oligonucleotide (ASO) development services, designed to address common technical bottlenecks in RNA therapeutics. The platform combines advanced bioinformatics, chemical synthesis, and rigorous preclinical validation to support biotechnology companies and academic institutions in accelerating pipeline progression.

Traditional ASO development often requires researchers to coordinate with multiple vendors for design, synthesis, and animal testing, leading to extended timelines and data inconsistency. Creative Biolabs aims to solve this by unifying the entire pipeline under one roof. The company's proprietary bioinformatic optimization utilizes thermodynamic simulation and RNA secondary structure accessibility prediction to identify optimal target regions, mitigating off-target risks from the outset.

The services include advanced chemical modification and synthesis capabilities, offering versatile oligonucleotide architectures such as Gapmers and steric-blocking oligos. Scales range from milligram to multi-gram, utilizing PS backbones, PMO, and sugar modifications (2'-MOE, cEt) to improve nuclease resistance and support in vivo stability. Precision delivery and conjugation technologies address cellular uptake barriers through custom targeted delivery, including GalNAc conjugation for liver targeting, Antibody-Oligonucleotide Conjugates (AOCs) for extrahepatic tissues, and specialized LNP formulations.

Robust preclinical validation provides data-rich in vitro screening (mRNA knockdown via qPCR, cytotoxicity testing) and in vivo PK/PD profiling to support preclinical candidate selection and further development planning. According to the Chief Scientific Officer at Creative Biolabs, many therapeutic pipelines stall because a high-affinity sequence fails under physiological conditions due to poor delivery or low stability. The one-stop platform eliminates these silos by matching customized chemical modifications with precise conjugation chemistries early in the design phase, significantly lowering required doses and improving safety profiles.

Creative Biolabs offers a robust portfolio of ready-to-use ASO products spanning oncology, genetic disorders, and neuromuscular diseases, providing the flexibility and technical expertise required to turn therapeutic concepts toward preclinical candidate development.